Christian Gastelum, MD
Endocrinology, Diabetes & Metabolism · Los Angeles, CANPI 1285782268
Payments from drug & device makers
Across 904 payments — averaging $466.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$202K
- Biotissue Holdings Inc.$90K
- Lilly USA, LLC$66K
- Abbott$28K
- Sanofi-aventis U.S. LLC$11K
- Eli Lilly$11K
- plus $13K from 33 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 370 | $202,426 |
| Biotissue Holdings Inc. | 47 | $89,896 |
| Lilly USA, LLC | 115 | $66,058 |
| Abbott | 115 | $28,272 |
| Sanofi-aventis U.S. LLC | 18 | $11,318 |
| Eli Lilly | 1 | $10,506 |
| Mannkind Corporation | 51 | $8,209 |
| Amgen(2 entities) | 43 | $955 |
| Dexcom, Inc. | 20 | $637 |
| AstraZeneca(2 entities) | 14 | $442 |
| Novartis | 17 | $344 |
| Insulet Corporation | 18 | $309 |
| Boehringer Ingelheim | 7 | $186 |
| Neurocrine Biosciences, Inc. | 4 | $134 |
| Bigfoot Biomedical Inc | 2 | $126 |
| Tandem Diabetes Care, Inc. | 7 | $122 |
| Medtronic(2 entities) | 5 | $115 |
| Kvk-tech, Inc. | 2 | $112 |
| Ascendis Pharma Endocrinology Inc | 5 | $110 |
| Currax Pharmaceuticals LLC | 6 | $105 |
| Johnson & Johnson | 5 | $97 |
| IBSA Pharma Inc. | 5 | $91 |
| Ascensia Diabetes Care US Inc. | 4 | $87 |
| Corcept Therapeutics | 3 | $77 |
| BD | 1 | $77 |
| Averitas Pharma Inc. | 2 | $62 |
| Bayer | 2 | $58 |
| Antares Pharma, Inc. | 2 | $48 |
| Stryker | 1 | $45 |
| Xeris Pharmaceuticals, Inc. | 2 | $42 |
| BETA Bionics, Inc. | 2 | $31 |
| Rhythm Pharmaceuticals, Inc. | 1 | $31 |
| Ionis Pharmaceuticals, Inc. | 1 | $26 |
| Recordati_rare_diseases_inc. | 1 | $25 |
| Sequel Med Tech, LLC | 1 | $24 |
| Madrigal Pharmaceuticals | 1 | $20 |
| Tolmar, Inc. | 1 | $17 |
| GSK | 1 | $15 |
| Embecta Corp. | 1 | $13 |
How this compares
$421,267 in reported general payments places this provider in the 90th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Los Angeles
- Stanley HsiaLos Angeles$19.8M
- Shlomo MelmedLos Angeles$3.3M
- Sina TebiLos Angeles$2.4M
- Anthony HeaneyLos Angeles$788K
- Jerrold OlefskySan Diego$26.5M
- Mark ChristiansenWalnut Creek$22.9M
- Timothy BaileyEscondido$22.3M
- Juan FriasSan Diego$14.1M
- Paul NorwoodFresno$6.2M
- Athena Philis-Tsimikasla Jolla$6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.